Skip to main navigation Skip to search Skip to main content

A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date10/20/15 → 10/19/21

Funding

  • Astellas Pharma Global Development Incorporated: $38,665.50